IgM monoclonal gammopathy of undetermined significance: clinicopathologic features with and without IgM-related disorders.
Journal
Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435
Informations de publication
Date de publication:
01 10 2023
01 10 2023
Historique:
received:
15
11
2022
medline:
5
10
2023
pubmed:
7
4
2023
entrez:
6
4
2023
Statut:
epublish
Résumé
A subset of patients with immunoglobulin M (IgM) monoclonal gammopathy of undetermined significance (MGUS) develop IgM-related disorders (IgM-RD) including peripheral neuropathy, cryoglobulinemia and/or cold agglutinin disease (CAD). We examined the clinical and bone marrow pathologic findings in 191 IgM MGUS patients (2016 World Health Oragnization criteria). Clonal plasma cells were identified in 41 of 171 (24%) cases by immunohistochemistry (IHC) and clonal B cells in 43 of 157 (27%). IgM-RD was identified in 82 (43%) cases, including peripheral neuropathy (n=67, 35%), cryoglobulinemia (n=21, 11%), and CAD (n=10, 5%). Cases of CAD showed distinctive features including lack of MYD88 mutations (P=0.048), supporting the concept of primary CAD as a distinct clinicopathologic disorder. Following exclusion of CAD, comparison of the remaining cases with (n=72) or without (n=109) IgM-RD showed IgM-RD to be more frequent in men than women (P=0.02) and to be more highly associated with MYD88 L265P (P=0.011). Cases with and without IgM-RD otherwise showed similar features including serum IgM concentrations, presence of lymphoid aggregates, clonal B cells by flow cytometry or clonal plasma cells by IHC. No differences were observed in overall survival between cases with and without IgM-RD. No cases in this series met criteria for plasma cell type IgM MGUS as defined in the 2022 International Consensus Classification of lymphoid neoplasms. These results show IgM-RD to be common in patients with IgM MGUS. While CAD shows distinctive features, the remaining cases of IgM-RD largely show pathologic findings similar to IgM MGUS without IgM-RD.
Identifiants
pubmed: 37021542
doi: 10.3324/haematol.2022.282389
pmc: PMC10543195
doi:
Substances chimiques
Myeloid Differentiation Factor 88
0
Immunoglobulin M
0
Antibodies, Monoclonal
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2764-2773Références
Ann Hematol. 2015 Jun;94(6):1011-6
pubmed: 25572169
Curr Hematol Malig Rep. 2020 Apr;15(2):45-55
pubmed: 32222885
Blood Adv. 2020 Mar 24;4(6):993-996
pubmed: 32168377
Am J Clin Pathol. 2022 Jan 6;157(1):47-53
pubmed: 34508562
Blood. 2022 Sep 15;140(11):1229-1253
pubmed: 35653592
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Blood. 2018 Oct 4;132(14):1478-1485
pubmed: 30012636
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Leukemia. 2014 Jan;28(1):166-73
pubmed: 23604227
Nat Rev Nephrol. 2019 Jan;15(1):45-59
pubmed: 30510265
Acta Neurol Scand. 1992 Jun;85(6):383-90
pubmed: 1379409
Blood. 2019 Jun 6;133(23):2484-2494
pubmed: 31010848
Blood. 2015 Apr 9;125(15):2370-80
pubmed: 25655603
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):380-388
pubmed: 33275738
Am J Hematol. 2017 Aug;92(8):746-751
pubmed: 28383205
Haematologica. 2022 Sep 01;107(9):2037-2050
pubmed: 35770530
Semin Oncol. 2003 Apr;30(2):110-5
pubmed: 12720118
Blood. 2018 Jan 11;131(2):163-173
pubmed: 29183887
Br J Haematol. 2018 Dec;183(5):838-842
pubmed: 29265349
Haematologica. 2014 Mar;99(3):497-504
pubmed: 24143001
Leukemia. 2020 Dec;34(12):3111-3125
pubmed: 33046818
Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):93-5
pubmed: 21454201
Br J Haematol. 2008 Mar;140(5):547-51
pubmed: 18275432
Cancers (Basel). 2020 Jun 25;12(6):
pubmed: 32630470
Front Oncol. 2022 Jun 09;12:905484
pubmed: 35756635
N Engl J Med. 2021 May 20;384(20):1931-1941
pubmed: 34010532